enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) was up 5.6% on Monday . The company traded as high as $0.76 and last traded at $0.76. Approximately 5,032 shares were traded during trading, a decline of 69% from the average daily volume of 16,072 shares. The stock had previously closed at $0.72.
enGene Trading Up 5.6 %
The stock has a 50-day simple moving average of $0.92 and a two-hundred day simple moving average of $1.25.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
- Five stocks we like better than enGene
- How to invest in marijuana stocks in 7 steps
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
